Barclays PLC Has $513,000 Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Barclays PLC lifted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 356.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 247,280 shares of the company’s stock after purchasing an additional 193,046 shares during the period. Barclays PLC’s holdings in Taysha Gene Therapies were worth $513,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth $931,000. State Street Corp increased its holdings in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Taysha Gene Therapies by 81.9% during the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after acquiring an additional 34,243 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after buying an additional 33,123 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at $85,000. Institutional investors own 77.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

TSHA stock opened at $1.85 on Friday. The stock’s fifty day moving average price is $2.10 and its 200-day moving average price is $2.18. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $379.14 million, a P/E ratio of 2.94 and a beta of 0.79. Taysha Gene Therapies, Inc. has a 1 year low of $1.19 and a 1 year high of $4.32.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.